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Background and Significance

Name/MRN:

Residence:

The successful enrollment of oncology patients in early
phase clinical trials requires clinical and research teams
to work together to identify an appropriate treatment
option for the patient. The screening process is laborintensive and requires both clinical knowledge and
knowledge of study protocol requirements. Advance
practice providers (APPs) are an important part of the
clinical team and are heavily involved in the patient
screening process. In this study, we assessed the
efficacy of utilizing a novel template, known as the
“Standardized Assessment for Clinical Trial Enrollment”
(SAFE) template, to assist both APPs and clinical trial
coordinators in screening patients for trial eligibility.

Diagnosis/Areas of
Metastatic Disease:

Is disease:
Yes
Measurable: ☐
Biopsy-able: ☐
Injectable:
☐

Methods

Current steroid use:
Yes ☐ No ☐

The SAFE template was utilized in six physician clinics
from November 2020 to February 2021 to screen new
patients and consultations for clinical trial enrollment in
early phase clinical trials. The trial enrollment rate for
each physician clinic from this period was compared to
the trial enrollment rate from April 2020 to July 2020
when the SAFE template was not utilized. The SAFE
template was completed by APPs and uploaded to
MOCLIA, which is the online portal containing
resources for trial enrollment, at least 24 hours before
the patient’s clinic visit. Study coordinators then utilized
the template to screen patients. The goal of the study
was to determine if completing the SAFE template
improved the enrollment rate on clinical trials.

Recent lab results:

CNS Involvement:
Yes ☐ No ☐

Oncologic History:

Past Medical History:

Last treatment date:
Prior hypersensitivity to
immunotherapy:
Yes ☐ No ☐
Current medications:

Molecular testing
results:

Symptoms/ECOG:

Table 1 Sample of SAFE template
Fig. 1 Clinical Trial Enrollment Rate by Clinic Before and After SAFE Implementation

Study Limitations
The baseline data before SAFE utilization was
collected shortly after the COVID-19 pandemic
started, which may have impacted baseline
enrollment rates. The actual utilization of the SAFE
template by clinical trial coordinators for screening
was not evaluated. Patients that are scheduled shortly
before their appointment date or are scheduled on the
actual date of the appointment limited utilization of
SAFE in these situations.

Results/Conclusion
A total of 256 new patients and consultations were
screened for trial enrollment using the SAFE template.
The trial enrollment rate increased in three clinics and
decreased in three clinics after the implementation of
the SAFE template. The average overall enrollment rate
for all six clinics combined decreased (56% to 49%).
For this reason, we assessed barriers to clinical trial
enrollment based on documentation in the electronic
health record from the clinical team. The most common
barrier to enrollment was that the patient either
continued standard of care (SOC) therapy or had
another SOC option (35% of patients). Patients may be
evaluated for trials proactively, before they have had
progression of disease on current treatment. Patients
would not be enrolled without evidence of progression
or poor tolerance. Other major barriers included poor
ECOG performance status (18%) and organ
dysfunction (16%). Most trials will require ECOG PS 0-1
and require adequate renal and liver function.

No
☐
☐
☐

Future Implications/Research

Fig. 2 Identified barriers to clinical trial enrollment

Educating referring providers, who request
consultations, and nursing staff on the new patient
team, who are responsible for compiling a patient
summary for acceptance of new patients, regarding
common barriers to clinical trial enrollment may ensure
that appropriate patients for clinical trial enrollment are
referred. This could increase overall enrollment rates
and ensure that the screening process is more efficient.
The nature of early phase clinical trials is that trial
openings and slot availability change frequently.
Therefore, if a patient is currently tolerating a standard
of care therapy without evidence of progression, it may
be prudent to defer consultation until the time of
progression. Close collaboration between the referring
provider and clinical trial team can also help the patient
in deciding on pursing a next line standard of care
therapy or pursuing a clinical trial.
.

